Safety and Efficacy Study Using Rexin-G for Sarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

June 30, 2011

Conditions
Sarcoma
Interventions
GENETIC

Rexin-G

Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity

GENETIC

Rexin-G

Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

GENETIC

Rexin-G

Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

GENETIC

Rexin-G

Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

GENETIC

Rexin-G

Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

Trial Locations (2)

90403

Sarcoma Oncology Center, Santa Monica

91108

Epeius Clinical Research Unit, San Marino

Sponsors
All Listed Sponsors
lead

Epeius Biotechnologies

INDUSTRY